Skip to main content
eScholarship
Open Access Publications from the University of California

Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.

  • Author(s): Calabrese, Daniel R
  • Aminian, Emily
  • Mallavia, Benat
  • Liu, Fengchun
  • Cleary, Simon J
  • Aguilar, Oscar A
  • Wang, Ping
  • Singer, Jonathan P
  • Hays, Steven R
  • Golden, Jeffrey A
  • Kukreja, Jasleen
  • Dugger, Daniel
  • Nakamura, Mary
  • Lanier, Lewis L
  • Looney, Mark R
  • Greenland, John R
  • et al.

Published Web Location

https://doi.org/10.1172/jci137047
Abstract

Pulmonary ischemia-reperfusion injury (IRI) is a clinical syndrome of acute lung injury that occurs after lung transplantation or remote organ ischemia. IRI causes early mortality and has no effective therapies. While NK cells are innate lymphocytes capable of recognizing injured cells, their roles in acute lung injury are incompletely understood. Here, we demonstrated that NK cells were increased in frequency and cytotoxicity in 2 different IRI mouse models. We showed that NK cells trafficked to the lung tissue from peripheral reservoirs and were more mature within lung tissue. Acute lung ischemia-reperfusion injury was blunted in a NK cell-deficient mouse strain but restored with adoptive transfer of NK cells. Mechanistically, NK cell NKG2D receptor ligands were induced on lung endothelial and epithelial cells following IRI, and antibody-mediated NK cell depletion or NKG2D stress receptor blockade abrogated acute lung injury. In human lung tissue, NK cells were increased at sites of ischemia-reperfusion injury and activated NK cells were increased in prospectively collected human bronchoalveolar lavage in subjects with severe IRI. These data support a causal role for recipient peripheral NK cells in pulmonary IRI via NK cell NKG2D receptor ligation. Therapies targeting NK cells may hold promise in acute lung injury.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View